Clinical trials: Lipids Metabolism
Fabry Disease
A Study of Replagal in Children and Adults With Fabry Disease in India
The main aim of this study is to learn more about the safety profile of Replagal. Participants will receive Replagal every 2 weeks at the clinic for about 1 year.
- Trial name
- NCT05067868
- Testing
- Replagal
- Where
- 3 sites in India
- Volunteers
- 5 people
- Sponsor
- Shire
Dyslipidemias
Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
The goal of this open label 16 week trial is to evaluate Lp(a) levels for patients with elevated Lp(a) being treated with obicetrapib and obiceptrapib/evolocumab Patients will: Have baseline Lp(a) tested at randomization Take…
- Trial name
- VINCENT (NCT06496243)
- Testing
- obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- NewAmsterdam Pharma
Type 2 Diabetes, Dyslipidemias
To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults
The purpose of this study is to evaluate pharmacokinetic interaction and safety of co-administrated 25mg of Empagliflozin and 10/10mg Ezetimibe/Rosuvastatin in steady state in healthy volunteers.
- Trial name
- NCT06578676
- Testing
- Empagliflozin 25 MG, Ezetimibe/Rosuvastatin 10/10mg, Empagliflozin 25 MG with Ezetimibe/Rosuvastatin 10/10mg
- Where
- South Korea
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Hyundai Pharm
Hypertension and Dyslipidemia
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg
A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-386(5)
- Trial name
- NCT05698043
- Testing
- CKD-386(5), D013, D326, D337
- Where
- South Korea
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Dyslipidemia
Compare the Pharmacokinetics of NVP-1205 and Coadministration of Rosuvastatin and Ezetimibe
The purpose of this study is to compare the pharmacokinetics of NVP-1205 and coadministration of rosuvastatin and ezetimibe.
- Trial name
- NVP-1205 (NCT02029625)
- Testing
- NVP-1205, rosuvastatin and ezetimibe
- Where
- South Korea
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- NVP Healthcare
Hypercholesterolemia, Hyperlipidemia
Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2)
This is a single-center, randomized, open-label, 3-period, 3-treatment multiple-dose crossover study designed to assess the interaction between VYTORIN® (Ezetimibe and Simvastatin) and NIASPAN® (Niacin Extended-Release Tablets)…
- Trial name
- NCT00652431
- Testing
- Vytorin + Niaspan, Vytorin, Niaspan
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Organon and Co
Hypercholesterolemia
Evaluation of Efficacy and Safety of AVE5530 in Patients With Primary Hypercholesterolemia
The present study is aiming at assessing the efficacy and safety of AVE5530 (25mg and 50mg) in a double-blind comparison with placebo in the management of patients with primary hypercholesterolemia.
- Trial name
- NCT00718965
- Testing
- AVE5530
- Where
- 2 sites in United States, Puerto Rico
- Volunteers
- 826 people
- Sponsor
- Sanofi
Hypertension and Dyslipidemia
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(3)
A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-348(3)
- Trial name
- NCT05192356
- Testing
- CKD-348(3), CKD-828, D097, D337
- Where
- South Korea
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
To Determine Bioequivalence Under Fed Conditions
Bioavailability Study of Leflunomide Tablets Under Fed Conditions
To compare the single-dose Bioavailability of Kali and Aventis
- Trial name
- NCT00653003
- Testing
- Leflunomide, ARAVA
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Par Pharmaceutical, Inc.
Dyslipidemia
A Two-arm, Open-label, Single-sequence, Multiple-dose, Cross-over Study to Evaluate the Pharmacokinetic Interaction and the Safety of UIC202502 and UIC202505 in Healthy Adult Volunteers
This study is open-label, multiple-dose, two-intervention group, single-sequence, crossover design to compare the safety and pharmacokinetics of UIC202502 and UIC202505 when administered alone or in combination.
- Trial name
- NCT07162441
- Testing
- treatment A, treatment B, treatment C
- Where
- South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Korea United Pharm. Inc.
Homozygous Familial Hypercholesterolemia
A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
This study was a Phase III,A two-part (double-blind placebo-controlled/open-label) multicenter study to evaluate safety, tolerability, and efficacy of inclisiran in subjects with homozygous familial hypercholesterolemia (HoFH).
- Trial name
- ORION-5 (NCT03851705)
- Testing
- Inclisiran Sodium for injection
- Where
- 13 sites in Hong Kong, Israel and 6 more
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Dyslipidemia
Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia
This is a randomized, double-blind, dose-ranging, placebo-controlled trial to determine the lipid-lowering efficacy and safety of BMS-298585 (muraglitazar) alone in combination with pravastatin in subjects with mixed dyslipidemia.
- Trial name
- NCT00245388
- Testing
- Muraglitazar
- Where
- 54 sites in United States, Canada
- Volunteers
- 330 people
- Sponsor
- Bristol-Myers Squibb
Dyslipidemia
Study of A3309 in Patients With Dyslipidemia
The purpose of this trial is to determine the efficacy and safety of A3309 administered to patients with dyslipidemia (high cholesterol levels).
- Trial name
- NCT01069783
- Testing
- A3309
- Where
- Sweden
- Volunteers
- 36 people
- Sponsor
- Albireo
Fabry Disease
Migalastat Food Effect Study
A 5-period crossover study to evaluate the effect of meal type and timing on migalastat HCl pharmacokinetics in healthy male and female subjects.
- Trial name
- NCT01489995
- Testing
- A (migalastat), B (migalastat), C (migalastat)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Amicus Therapeutics
Hypercholesterolaemia
An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
Primary Objective: To evaluate the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C) levels after 8 weeks of treatment in heterozygous familial hypercholesterolemia (heFH) participants aged of 8 to 17 years…
- Trial name
- ODYSSEY KIDS (NCT02890992)
- Testing
- alirocumab SAR236553 (REGN727), statins, ezetimibe
- Where
- 16 sites in United States, Canada and 8 more
- Volunteers
- 42 people
- Sponsor
- Sanofi
Dyslipidemia
Observational Study To Evaluate Statins Patterns Of Use In Spain
The present project is aimed at describing the statins prescription pattern in Spanish patients. It will also look into how adequate these prescriptions are accordingly to the recommendations given in Treatment Guidelines and in…
- Trial name
- NCT01023503
- Where
- Spain
- Sponsor
- AstraZeneca
High Triglycerides
Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia
This is a Phase IIa,multicentre proof of concept study consisting of 2 study periods to study Treatment with NST-1024 as an adjunct to diet to reduce triglyceride (TG) levels in subjects with TG levels of ≥500 mg/dL and ≤2000…
- Trial name
- NCT05889156
- Testing
- NST-1024
- Where
- 31 sites in United States
- Volunteers
- 50 people
- Sponsor
- NorthSea Therapeutics B.V.
Familial Partial Lipodystrophy, Metabolic Abnormalities
A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)
Two cohorts are being studied based on leptin levels. Cohort A is composed of patients with baseline leptin <8.0 ng/mL and Cohort B is composed of patients with baseline leptin 8.0 to ≤20.0 ng/mL The primary objectives will be…
- Trial name
- LEAP (NCT05088460)
- Testing
- REGN4461
- Where
- 8 sites in United States, France and 2 more
- Volunteers
- 20 people
- Sponsor
- Regeneron Pharmaceuticals
Dyslipidemia, Healthy Volunteers
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients
This study will assess the safety, tolerability, and effect of TAP311 on blood lipids in healthy subjects and in patients who have dyslipidemia.
- Trial name
- NCT01487460
- Testing
- TAP311
- Where
- United States
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Gaucher Disease Type 1
Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher Disease
Although miglustat has been approved as a treatment for mild to moderate type 1 Gaucher disease in patients who are unsuitable for enzyme replacement therapy (ERT), more data are required to establish the long term efficacy…
- Trial name
- NCT00319046
- Testing
- Miglustat
- Volunteers
- 42 people
- Sponsor
- Actelion
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.